India imposes 30 pct margin cap on cancer medicines prices
Summary
India has imposed a 30 percent margin cap on non-scheduled cancer medicines after complaints of exorbitant prices. The government says the move will save cancer patients around 25 billion rupees annually.
Key Points
- India has capped the maximum retail price margin on non-scheduled cancer drugs at 30 percent.
- The government says the policy could save cancer patients about 25 billion Indian rupees each year.
- Scheduled essential cancer medicines were already subject to government ceiling prices.
- Non-scheduled anti-cancer drugs were found to carry average mark-ups of about 170 percent, and in some cases 700 percent or more.
